SHP1705

SHP1705 is a novel small-molecule Cryptochrome (CRY) activator, specifically targeting the CRY2 isoform, developed by Synchronicity Group. It functions by restoring activity to the CRY2 protein, which in turn inhibits the BMAL1-CLOCK transcriptional apparatus. This mechanism is designed to disrupt the circadian clock machinery that certain cancers, such as microsatellite-stable colorectal cancer (MSS CRC) and glioblastoma, exploit to drive metabolic processes. SHP1705 has demonstrated safety and tolerability in a Phase 1 clinical trial involving healthy volunteers and has shown preclinical synergy with bevacizumab in MSS CRC models. Clinical development is progressing toward Phase 2 trials for glioblastoma, where it is intended to enhance the efficacy of standard treatments including surgery, chemotherapy, and radiation.